🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being described as a "significant breakthrough" in the fight against increasingly resistant strains of the pathogen, according to health experts.

A Global Health Concern

Cases of gonorrhoea are escalating worldwide, with estimates suggesting in excess of 82 million new cases annually. Especially elevated rates are reported in Africa and nations within the WHO's designated area, which includes Mongolia and China to New Zealand. Across England, cases have hit a record high, while rates across Europe in 2023 were significantly elevated compared to those in 2014.

“The authorization of new treatments for gonorrhoea is an important and timely development in the context of increasing worldwide cases, increasing antimicrobial resistance and the very limited treatment choices at this time.”

Public health authorities are particularly alarmed about the surge in antibiotic-resistant strains. The WHO has listed it as a "priority pathogen". Recent surveillance revealed that the effectiveness of standard treatments like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Treatment Options Gain Authorization

One new antibiotic, also known as Nuzolvence, was approved by the US Food and Drug Administration in December for combating gonorrhoea. This infection can lead to significant complications, including infertility. Scientists hope that focused deployment of this new drug will help hinder the spread of drug resistance.

Gepotidacin, originating from the drugmaker GlaxoSmithKline, was also approved in concurrent days. This medication, which is employed against urinary tract infections, was demonstrated in studies to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin stemmed from a new, not-for-profit approach for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the drug firm its industry partner to see it through.

“This authorization marks a significant shift in the therapy of multidrug-resistant gonorrhoea, which until now has been staying ahead of our drug pipeline.”

Testing Data and Global Access

Based on data published in a major medical journal, the new drug successfully treated more than 90% of cases of the STI. This places it at an similar efficacy with the typical regimen, which combines an injection and a pill. The study enrolled nearly 1,000 patients from multiple nations including the United States, Thailand, South Africa, and European nations.

Under the terms of its development partnership, the non-profit has the ability to register and commercialise the drug in many low-income and middle-income countries.

Clinicians on the front lines have shared hope. The availability of a one-pill regimen such as this is seen as a "critical tool" for public health efforts. This is viewed as vital to reduce the burden of the infection for individuals and to prevent the spread of extremely resistant gonorrhoea around the world.